Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

To join this study, adult participants must have been diagnosed with a specific type of follicular lymphoma (CD20+, Grade 1 to 3a) that has spread to certain areas of the body (Stage III, IV, or II with a large tumour). Your doctor must also believe that you need treatment for your lymphoma.

You'll need to have had specific scans (PET/CT) showing the lymphoma, and certain blood test results must meet the study's requirements. You should also be generally well enough to take part in the study activities.

There are also some reasons why you might not be able to join. For example, if you've had major surgery very recently or if you have an active serious viral infection like cytomegalovirus (CMV).

If you decide to take part, you'll be assigned to one of five different treatment groups. Each group will receive a different combination of drugs. These treatments will involve a mix of injections under the skin (subcutaneous), injections into a vein (intravenous infusion), and tablets or capsules you take by mouth.

The treatment period will last for either 24 weeks or 120 weeks, depending on which treatment group you are in. Throughout this time, you'll have regular visits to a hospital or clinic. These visits will include medical check-ups, blood tests, and health questionnaires to monitor your progress and check for any side effects. Your doctor will carefully watch how you're responding to the treatment.